Project Grant R21TR004695
Award Date
8/1/24
Completion Date
7/31/26
Dollars Obligated
$429K
Federal Agency
National Center for Advancing Translational Sciences
Federal Grant Program
93.350
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
This $15,782,145 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will support the conduct of a randomized, placebo-controlled, Phase 2 clinical trial platform to simultaneously test multiple therapies for progressive supranuclear palsy (PSP), a severe neurodegenerative disease. The overarching goal is to efficiently evaluate the safety, tolerability, and clinical proof-of-concept of at least three different tau-related or neuroprotective...
This federal Project Grant awarded by the National Institute on Aging under CFDA 93.866 (Aging Research) aims to examine the role of specific phenotypes, such as sex/gender, APOE4 status, and polygenic hazard scores, on response to drug or lifestyle interventions in existing Alzheimer's disease clinical trials datasets. The $3,281,385 grant, awarded on September 1, 2024, will leverage data from 14,602 participants in 30 years of Alzheimer's clinical trials to analyze the impact of these...
This $456,348 federal Project Grant award from the National Center for Advancing Translational Sciences (NCATS) with CFDA Program 93.350 aims to develop a consensus-driven measurement strategy for assessing cognitive function in patients with immune thrombotic thrombocytopenic purpura (iTTP), a rare and serious blood disorder. The study will first use qualitative interviews to develop a conceptual model of iTTP-induced cognitive impairment. It will then leverage a literature review and...
This Project Grant award, funded by the National Center for Advancing Translational Sciences (NCATS, CFDA# 93.350), provides $199,355 to the Children's Hospital of Philadelphia (CHOP) over the period of May 1, 2024 to April 30, 2027. The award supports the Predoctoral Preparatory Program (P3) in Translational Research, a one-year education program focused on building research and professional skills for junior research coordinators working within the Global Leukodystrophy Initiative Clinical...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $234,000.00 in funding to the University of Colorado-Denver to develop and pilot a patient decision aid (DA) to support shared decision-making between clinicians, patients, and caregivers regarding pharmacologic therapies for dementia. The key products to be delivered under this 2-year award include: 1) conducting a qualitative needs assessment among eligible patients, caregivers, and...
This federal Project Grant award of $1,340,036.00, provided by the National Institute on Aging (CFDA 93.866 Aging Research), aims to develop methods to characterize patients who highly benefit on multiple clinical outcomes from treatments for Alzheimer's disease and related dementias (ADRD). The key products or services to be delivered under this grant include: Methods to accurately characterize patients who experience high benefits across multiple ADRD treatment outcomes, such as reduced...
This $209,067 federal Project Grant award was made by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) to The Regents of the University of California, San Francisco (UCSF) on May 17, 2024. The primary objective of this research project is to evaluate several important clinical decisions commonly encountered by primary care providers (PCPs) when caring for patients experiencing cognitive decline or Alzheimer's disease and related dementias (ADRD). Specifically,...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $800,700 in funding to The Regents of the University of California, San Francisco (UCSF) to conduct a longitudinal, multimodal imaging study. The goal is to elucidate the role of neuronal dysfunction and hyperexcitability in the early biological progression of Alzheimer's disease. The study will identify the earliest manifestations of neural circuit hyperexcitability that predict the...
This $110,000 Project Grant award from the National Center for Advancing Translational Sciences (NCATS) under CFDA 93.350 supports research by Greenstone Biosciences, Inc. to develop advanced drug discovery and development technologies for rare genetic disorders. The project aims to leverage induced pluripotent stem cell (iPSC) technology and artificial intelligence/machine learning (AI/ML) to accelerate and streamline the drug discovery process for myotonic dystrophy type 1 (DM1), a rare and...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $575,667 to the University of Mississippi Medical Center to investigate the role of activated protein C (APC) signaling in the pathogenesis of Alzheimer's disease (AD). The research aims to characterize how APC signaling impacts the metabolic and inflammatory processes that contribute to AD, as well as evaluate the potential of APC derivatives to improve neurological function and...